Using the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria to determine the diagnosis of systemic lupus erythematosus (SLE) in patients with subacute cutaneous lupus erythematosus (SCLE) - 14/04/16
Abstract |
Background |
Approximately 50% of patients with subacute cutaneous lupus erythematosus (SCLE) meet criteria for systemic lupus erythematosus (SLE). The Systemic Lupus International Collaborating Clinics (SLICC) developed new SLE criteria to improve the American College of Rheumatology (ACR) criteria but the SLICC criteria have not been evaluated in patients with SCLE.
Objective |
We sought to determine how patients with SCLE/SLE meet the ACR and SLICC criteria to compare the 2 sets of criteria.
Methods |
This was a retrospective analysis of 107 patients with SCLE enrolled in a database at the University of Pennsylvania.
Results |
Patients with SCLE/SLE were more likely than those with only SCLE to have oral ulcers, positive anti-double-stranded DNA antibodies, and positive antinuclear antibody test findings using both sets of criteria. Patients with SCLE/SLE were also more likely to have low complement using the SLICC criteria. There was a statistically insignificant increase in individuals meeting the SLICC criteria.
Limitations |
Not all patients received comprehensive laboratory testing.
Conclusions |
Most patients with SCLE who formally meet criteria for SLE do so based on the laboratory and mucocutaneous criteria. Neither the ACR nor SLICC criteria distinguish patients with SCLE and major internal disease from patients with SCLE without major internal disease.
Le texte complet de cet article est disponible en PDF.Key words : American College of Rheumatology, classification criteria, cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, systemic lupus erythematosus, Systemic Lupus International Collaborating Clinics
Abbreviations used : ACR, ANA, CLE, dsDNA, SCLE, SLE, SLICC
Plan
| Supported by the Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development (5 I01 BX000706-04, Dr Werth), and National Institutes of Health (NIH K24-AR 02207; Dr Werth). |
|
| Conflicts of interest: None declared. |
Vol 74 - N° 5
P. 862-869 - mai 2016 Retour au numéro
Article précédent
- Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])
- Bruce E. Strober, Robert Bissonnette, David Fiorentino, Alexa B. Kimball, Luigi Naldi, Neil H. Shear, Kavitha Goyal, Steven Fakharzadeh, Stephen Calabro, Wayne Langholff, Yin You, Claudia Galindo, Seina Lee, Mark G. Lebwohl
- Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-V? chain restriction
- Juliet F. Gibson, Jing Huang, Kristina J. Liu, Kacie R. Carlson, Francine Foss, Jaehyuk Choi, Richard Edelson, Jerry W. Hussong, Ramsey Mohl, Sally Hill, Michael Girardi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?